With a positive Phase III trial finally in hand for its antidepressant candidate ALKS 5461 for the targeted population of treatment-resistant patients with major depressive disorder, Alkermes thinks it has the right data package to gain approval and make an impact on the market.
Just nine months after announcing clinical data suggesting that ALKS 5461 (buprenorphine/samidorphan) had marginal clinical efficacy and very little chance...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)